Immunotherapy Before and After Surgery

NCT06765902 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study was redeveloped into a new protocol

Conditions

High-risk Prostate Cancer

Interventions

DRUG: N-803
DRUG: ETBX-071
DRUG: M-CENK

Sponsor

ImmunityBio, Inc.